Astria Therapeutics Inc Financials
This page shows Astria Therapeutics Inc (ATXS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Astria’s operating model is converting fresh equity capital into clinical R&D spending, rather than funding growth through sales or debt.
Cash burn intensified in the latest year, with operating cash outflow reaching$81.2M while ending cash was only$59.8M ; that tells you the larger accounting loss was also a real cash event, not mainly non-cash noise. Even so, total assets expanded because financing inflows of$157.2M outweighed that burn, leaving the balance sheet larger at$342.4M despite no operating revenue.
Capital intensity is scientific, not physical: capex was just
Borrowing is not the main support, with liabilities of only
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Astria Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Astria Therapeutics Inc carries a low D/E ratio of 0.07, meaning only $0.07 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 17.49, Astria Therapeutics Inc holds $17.49 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Astria Therapeutics Inc generates a -29.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -30.0% the prior year.
Astria Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Astria Therapeutics Inc generates $0.86 in operating cash flow (-$81.2M OCF vs -$94.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Astria Therapeutics Inc reported -$94.3M in net income in fiscal year 2024. This represents a decrease of 29.3% from the prior year.
Astria Therapeutics Inc earned $-1.68 per diluted share (EPS) in fiscal year 2024. This represents an increase of 30.6% from the prior year.
Cash & Balance Sheet
Astria Therapeutics Inc generated -$81.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 19.1% from the prior year.
Astria Therapeutics Inc held $59.8M in cash against $0 in long-term debt as of fiscal year 2024.
Astria Therapeutics Inc had 56M shares outstanding in fiscal year 2024. This represents an increase of 37.5% from the prior year.
Margins & Returns
Astria Therapeutics Inc's ROE was -29.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the prior year.
Capital Allocation
Astria Therapeutics Inc invested $77.1M in research and development in fiscal year 2024. This represents an increase of 83.0% from the prior year.
Astria Therapeutics Inc invested $325K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 1200.0% from the prior year.
ATXS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $706K | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $24.1M-6.9% | $25.9M-6.6% | $27.8M | N/A | $20.5M-1.0% | $20.7M+31.7% | $15.7M | N/A |
| SG&A Expenses | $10.7M+8.0% | $9.9M+7.2% | $9.2M | N/A | $8.5M+5.1% | $8.1M-3.9% | $8.4M | N/A |
| Operating Income | -$34.1M+4.8% | -$35.8M+3.2% | -$37.0M | N/A | -$29.0M-0.7% | -$28.8M-19.3% | -$24.1M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$31.6M+4.3% | -$33.1M+1.9% | -$33.7M | N/A | -$24.5M-1.5% | -$24.2M-21.3% | -$19.9M | N/A |
| EPS (Diluted) | $-0.55+3.5% | $-0.57+1.7% | $-0.58 | N/A | $-0.42+2.3% | $-0.43-13.2% | $-0.38 | N/A |
ATXS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $271.9M-3.6% | $281.9M-9.2% | $310.4M-9.3% | $342.4M-5.3% | $361.6M-1.7% | $368.0M-2.9% | $378.8M+48.7% | $254.7M |
| Current Assets | $253.5M-5.6% | $268.6M-11.3% | $303.0M-9.5% | $334.6M-4.9% | $351.9M-1.7% | $357.9M-4.4% | $374.5M+49.2% | $250.9M |
| Cash & Equivalents | $96.3M+26.2% | $76.3M+40.3% | $54.4M-9.1% | $59.8M-26.1% | $80.9M-7.2% | $87.2M-49.3% | $172.0M-2.0% | $175.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $17.2M | N/A | N/A | $0 | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $38.6M+80.3% | $21.4M+1.5% | $21.1M-8.7% | $23.1M+15.6% | $20.0M-4.4% | $20.9M+88.9% | $11.1M-4.1% | $11.6M |
| Current Liabilities | $23.5M+30.3% | $18.0M+3.5% | $17.4M-8.9% | $19.1M+21.7% | $15.7M-3.9% | $16.4M+47.8% | $11.1M-4.1% | $11.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $233.3M-10.5% | $260.5M-9.9% | $289.3M-9.4% | $319.3M-6.6% | $341.7M-1.6% | $347.1M-5.6% | $367.7M+51.3% | $243.1M |
| Retained Earnings | -$773.2M-4.3% | -$741.6M-4.7% | -$708.5M-5.0% | -$674.8M-3.9% | -$649.2M-3.9% | -$624.6M-4.0% | -$600.5M-3.4% | -$580.5M |
ATXS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.3M+10.4% | -$36.1M-6.0% | -$34.0M-95.9% | -$17.4M+37.9% | -$28.0M-66.5% | -$16.8M+12.1% | -$19.1M+36.9% | -$30.2M |
| Capital Expenditures | $0 | N/A | N/A | $0-100.0% | $20K | N/A | N/A | $16K |
| Free Cash Flow | -$32.3M | N/A | N/A | -$17.4M+38.0% | -$28.0M | N/A | N/A | -$30.3M |
| Investing Cash Flow | $52.3M-9.9% | $58.0M+102.9% | $28.6M+869.0% | -$3.7M-160.1% | $6.2M+109.1% | -$68.1M+46.0% | -$126.2M-6161.5% | -$2.0M |
| Financing Cash Flow | N/A | N/A | N/A | $0-100.0% | $15.3M+16177.7% | $94K-99.9% | $141.8M+61.2% | $88.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ATXS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -4830.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -4482.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -13.6%-0.9pp | -12.7%-1.0pp | -11.7% | N/A | -7.2%-0.2pp | -7.0%-1.5pp | -5.4% | N/A |
| Return on Assets | -11.6%+0.1pp | -11.7%-0.9pp | -10.9% | N/A | -6.8%-0.2pp | -6.6%-1.3pp | -5.3% | N/A |
| Current Ratio | 10.78-4.1 | 14.89-2.5 | 17.39-0.1 | 17.49-4.9 | 22.38+0.5 | 21.87-12.0 | 33.83+12.1 | 21.73 |
| Debt-to-Equity | 0.17+0.1 | 0.080.0 | 0.070.0 | 0.07+0.0 | 0.060.0 | 0.06+0.0 | 0.03-0.0 | 0.05 |
| FCF Margin | -4574.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Astria Therapeutics Inc profitable?
No, Astria Therapeutics Inc (ATXS) reported a net income of -$94.3M in fiscal year 2024.
What is Astria Therapeutics Inc's return on equity (ROE)?
Astria Therapeutics Inc (ATXS) has a return on equity of -29.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Astria Therapeutics Inc's free cash flow?
Astria Therapeutics Inc (ATXS) generated -$81.5M in free cash flow during fiscal year 2024. This represents a -19.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Astria Therapeutics Inc's operating cash flow?
Astria Therapeutics Inc (ATXS) generated -$81.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Astria Therapeutics Inc's total assets?
Astria Therapeutics Inc (ATXS) had $342.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Astria Therapeutics Inc's capital expenditures?
Astria Therapeutics Inc (ATXS) invested $325K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Astria Therapeutics Inc spend on research and development?
Astria Therapeutics Inc (ATXS) invested $77.1M in research and development during fiscal year 2024.
What is Astria Therapeutics Inc's current ratio?
Astria Therapeutics Inc (ATXS) had a current ratio of 17.49 as of fiscal year 2024, which is generally considered healthy.
What is Astria Therapeutics Inc's debt-to-equity ratio?
Astria Therapeutics Inc (ATXS) had a debt-to-equity ratio of 0.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Astria Therapeutics Inc's return on assets (ROA)?
Astria Therapeutics Inc (ATXS) had a return on assets of -27.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Astria Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Astria Therapeutics Inc (ATXS) had $59.8M in cash against an annual operating cash burn of $81.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Astria Therapeutics Inc's Piotroski F-Score?
Astria Therapeutics Inc (ATXS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Astria Therapeutics Inc's earnings high quality?
Astria Therapeutics Inc (ATXS) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Astria Therapeutics Inc?
Astria Therapeutics Inc (ATXS) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.